Clinical trial · Observational
Prolactin Receptor and Breast Diseases
Characterization and Implication of Prolactin Receptor Mutants in Human Breast Diseases
NCT00842465CI-TRIAL-00012742ProlacseincompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes. The aim of this project is to identify and to characterize new mutants of the prolactin receptor gene within cohorts of benign or malign breast diseases with low or high occurrence frequency in human populations
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Breast Disease | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood collection | Genetic | — | UNRESOLVED |
| blood collection for hormonal status analysis | Biological | — | UNRESOLVED |
| breast Biopsy or surgery | Procedure | — | UNRESOLVED |
| ultrasonography (pelvis and breast), bone mineral density | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- 1
- description
- benign breast diseases
- interventionNames
- Biological: blood collection for hormonal status analysis
- Procedure: breast Biopsy or surgery
- Genetic: blood collection
- Other: ultrasonography (pelvis and breast), bone mineral density
- label
- 2
- description
- breast cancer
- interventionNames
- Biological: blood collection for hormonal status analysis
- Procedure: breast Biopsy or surgery
- Genetic: blood collection
- Other: ultrasonography (pelvis and breast), bone mineral density
- label
- 3
- description
- control
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 10 Years
Show eligibility criteria text
Inclusion criteria : * benign breast diseases * 10 \< age \< 25 for simple FA * 10 \< age \< 50 for other diseases .no hormonal treatment for at least 3 months if patients took cyproterone acetate; 1 month for other ovaries-interfering hormonal treatment, and 1 week for ovaries-non-interfering hormonal treatments. * Signature of the informed consent form (icf) by patients or their legal representative (for patients under age of 18.) * breast cancer : * having a breast cancer with a planned surgery * age \> 55 years * post menopausal with not menopause substitution treatment * signature of the icf * control group : * 18 \< age \< 60 * signature of the icf Exclusion criteria : * no signature or no conformity of the icf * no social security
References
Publications (0)
Data not yet available
No reference posted for this study.